Disclosed is the use of milnacipran or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of fibromyalgia wherein the medicament is adapted for administration according to the following schedule a) administration of up to 25 mg of milnacipran or a pharmaceutically acceptable salt thereof per day for up to 3 days then b) administration of 50 mg of milnacipran or a pharmaceutically acceptable salt thereof per day for up to 5 days then c) administration of 100 mg of milnacipran or a pharmaceutically acceptable salt thereof per day.
